Navigation Links
Intrinsic Therapeutics' Barricaid and Magellan Spine Technologies' DART to Drive European Annulus Repair Market
Date:6/29/2009

Two new products to allow for additional spine treatments performed during discectomy procedures, according to Millennium Research Group

WALTHAM, Mass., June 29 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, new annulus repair devices that have entered the European spinal implant market will be key factors contributing to market growth through 2013. MRG's European Markets for Spinal Implants 2009 report finds that the annulus repair segment will form a niche market within the European spinal implant market that will exceed $670 million by 2013.

In April 2009, the first annulus repair device became available in Europe when Intrinsic Therapeutics' Barricaid device received CE marking. Later that month, Magellan Spine Technologies' Disc Annular Repair Technology (DART) System was also granted approval. As these and other companies increasingly promote their products and train surgeons to use them, adoption of annulus repair devices will grow rapidly through 2013.

"Through 2013 and beyond, companies will continue their efforts to demonstrate the benefits of combining annulus repair devices with discectomies, namely fewer costly revisions," says Kevin Flewwelling, Manager of MRG's Orthopedics division. "This will not only boost surgeon confidence in the procedures, which at the moment is low because the devices are so new, but it will also encourage governments and regulatory bodies across Europe to grant reimbursement for annulus repair devices because it will reduce the number of expensive discectomy revisions."

The accumulation of clinical evidence and socioeconomic data that displays how governments can save money by reducing discectomy revisions will be supported by the entrance of new competitors, such as Anulex Technologies, the 2008 leader of the US annulus repair market. The growth of leading competitors, such as Intrinsic Therapeutics and Anulex Technologies, will result in additional resources available to promote annulus repair technology to European surgeons and governments. This will drive uptake of annulus repair devices and expand procedure volumes.

MRG's European Markets for Spinal Implants 2009 report provides various segments of the spinal fusion implant market as well as the market for spinal nonfusion treatments, such as interspinous process decompression devices, pedicle screw-based dynamic stabilization systems, artificial discs, nuclear disc prostheses, annulus repair devices, and facet arthroplasty devices. This report allows clients to assess the effects of the economic downturn, plan for the future, tap into deep segmentation, and leverage up-to-date market shares and in-depth qualitative insights for France, Germany, Italy, Spain and the UK.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis
2. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
3. Prospect Therapeutics Inc.s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers
4. Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
5. Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations
6. Leaders from the Field of Pain Therapeutics to Discuss Latest Discoveries and Breakthroughs at Arrowhead's 3rd Annual Pain Therapeutics Summit
7. Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System
8. Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
9. Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
10. Prospect Therapeutics In Vitro Studies Demonstrate that GCS-100 Drug Binds to and Blocks the Effects of Galectin-3
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology: